Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Cost of Revenue (2016 - 2025)

Marimed (MRMD) has disclosed Cost of Revenue for 15 consecutive years, with $24.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 2.47% to $24.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $97.1 million, a 7.42% increase, with the full-year FY2024 number at $95.1 million, up 15.02% from a year prior.
  • Cost of Revenue was $24.4 million for Q3 2025 at Marimed, up from $23.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $26.3 million in Q4 2024 to a low of $11.5 million in Q1 2021.
  • A 5-year average of $19.7 million and a median of $20.1 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: soared 341.01% in 2021, then increased 0.21% in 2025.
  • Marimed's Cost of Revenue stood at $15.6 million in 2021, then increased by 28.7% to $20.0 million in 2022, then increased by 7.81% to $21.6 million in 2023, then grew by 21.83% to $26.3 million in 2024, then fell by 7.2% to $24.4 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Cost of Revenue are $24.4 million (Q3 2025), $23.6 million (Q2 2025), and $22.8 million (Q1 2025).